Cystic Fibrosis

Goals for the Session

  • Contrast Mucus Clearance:

    • Compare normal airway mucus clearance with the impaired clearance mechanism in Cystic Fibrosis (CF).

  • Recognize Inflammation in CF:

    • Identify that airway inflammation in CF is primarily neutrophilic in nature.

  • Organisms and Treatments in CF:

    • Describe organisms that cause endobronchial infections in CF and outline available treatments.

  • Clinical Findings and Treatment Options in CF:

    • Recognize clinical manifestations of CF and discuss treatment options, including modulators.

Manifestations of Cystic Fibrosis

General

  • Growth failure due to malabsorption

  • Vitamin deficiency states, specifically vitamins A, D, E, K.

Nose and Sinuses

  • Associated conditions include:

    • Nasal polyps

    • Sinusitis.

Liver

  • Potential liver issues:

    • Hepatic steatosis

    • Portal hypertension.

Gallbladder

  • Conditions related to gallbladder:

    • Biliary cirrhosis

    • Neonatal obstructive jaundice

    • Cholelithiasis.

Bone

  • Concerns in bone health include:

    • Hypertrophic osteoarthropathy

    • Clubbing

    • Arthritis

    • Osteoporosis.

Intestines

  • Potential issues include:

    • Meconium peritonitis

    • Meconium ileus

    • Rectal prolapse

    • Intussusception

    • Volvulus

    • Fibrosing colonopathy (strictures)

    • Appendicitis

    • Intestinal atresia

    • Distal intestinal obstruction syndrome

    • Inguinal hernia.

Lung Complications

  • Manifestations in the lungs are serious:

    • Bronchiectasis

    • Bronchitis

    • Bronchiolitis

    • Pneumonia

    • Atelectasis

    • Hemoptysis

    • Pneumothorax

    • Reactive airway disease

    • Cor pulmonale

    • Respiratory failure

    • Mucoid impaction of the bronchi

    • Allergic bronchopulmonary aspergillosis.

Heart

  • Changes in cardiac structure:

    • Right ventricular hypertrophy

    • Pulmonary artery dilation.

Spleen

  • Possible complications include hypersplenism.

Stomach

  • Gastroesophageal reflux disease (GERD).

Pancreas

  • Issues with the pancreas include:

    • Pancreatitis

    • Insulin deficiency leading to:

    • Symptomatic hyperglycemia

    • Diabetes.

Reproductive System

  • Reproductive problems detailed include:

    • Infertility (aspermia, absence of vas deferens)

    • Amenorrhea

    • Delayed puberty.

Hallmarks of Cystic Fibrosis

  • Skin often presents as very salty-tasting.

  • Patients may exhibit:

    • An appetite but poor growth and weight gain.

    • Symptoms such as coughing, wheezing, and shortness of breath.

    • Frequent lung infections, including pneumonia and bronchitis.

Pathophysiology of Cystic Fibrosis

  • Cystic Fibrosis arises from an abnormality of chloride channels in epithelial cells.

  • Diagnosis confirmed by a sweat chloride concentration exceeding 60 mmol/L.

  • Clinical manifestations primarily result from obstruction in tissues featuring tubular epithelial structures, including:

    • Mucus accumulation in lungs and sinuses

    • Pancreatic insufficiency occurring in approximately 85% of patients

    • Hepatobiliary complications

    • Bowel obstructions

    • Male infertility and relative female infertility.

  • The median survival for children born between 2020-2024 is approximately 65 years.

Data on Cystic Fibrosis

Statistics on Registries and Population

  • A chart describes the number of people with CF across states:

    • Significant variability, state-specific numbers range:

    • <99 to ≥1,000 individuals with CF.

  • The 2024 Race Distribution of the CF Population is documented as:

    • Majority are White (90.8%)

    • Black or African American: 3.4%

    • Hispanic/Latino, Multiracial, and Others make up over 23% of newly diagnosed individuals, reflecting increasing diversity in the population.

CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)

  • CFTR serves as a critical ion channel regulating chloride and other ion channels.

Complications from Epithelial Tube Obstruction

  • Complications due to obstruction of epithelial-lined tubes include:

    1. Pancreatic insufficiency

    2. Bowel obstruction

    3. Hepatobiliary disease

  • Pulmonary complications causing death in approximately 85% of patients.

The Bicarbonate Hypothesis

  • The hypothesis concerning CFTR dysfunction:
    Cl−+HCO<em>3−+Na++H</em>2OCl^- + HCO<em>3^- + Na^+ + H</em>2O

  • It suggests that in healthy individuals, bicarbonate ions facilitate mucus hydration and clearance, which is compromised in individuals with CF.

Sweating Test for Diagnosis of Cystic Fibrosis

  • The sweat test procedure explained:

    1. Electric stimulation to drive sweat from sweat glands.

    2. Collection of sweat on filter paper.

    3. High chloride concentration suggests CFTR mutation.

The Vicious Cycle in CF

  • Components of the cycle:

    • Obstruction causes: inflammation, infection, and further obstruction.

  • Consequences include:

    • Excessive sodium absorption

    • Lack of chloride secretion leading to deficient mucociliary transport.

Mucociliary Clearance in Healthy Airways vs CF Airways

  • Healthy airways: maintain adequate levels of periciliary liquid (PCL).

  • CF airways: experience depletion of airway surface liquid, compromising the mucociliary escalator that clears pathogens and particles effectively.

Methods to Relieve Airway Obstruction in CF

  1. Physical Methods:

    • Chest physiotherapy (CPT) and postural drainage.

    • Use of external vibrational devices (e.g., Metaneb).

    • Positive pressure devices (e.g., Acapella, Flutter).

    • Exercise and proper breathing techniques.

  2. Ion Channel Approaches:

    • Hydrating mucus using 7% hypertonic saline or mannitol.

    • Modifying mucus properties with DNase or other agents.

Treatment Goals for Cystic Fibrosis

  • Active Participation in Management:

    • Education and involvement of parents and patients in self-management.

  • Promote Adequate Growth through:

    • Pancreatic enzyme and vitamin supplementation, high-calorie diet.

  • Prevent Complications:

    • Immunizations and limiting environmental exposures.

  • Regular Airway Clearance Techniques (ACT).

Common Infections and Bacteria in CF

  1. Pseudomonas aeruginosa responsible for the primary threat (23% prevalence at around age 5).

  2. Other bacteria of concern:

    • Staph. aureus (methicillin-resistant: MRSA)

    • Stenotrophomonas maltophilia

    • Burkholderia cepacia complex.

Antibiotics for Infection Management in CF

  • Employs antibiotics in various forms:

    • Oral antibiotics: Amoxicillin, cephalexin.

    • Inhaled antibiotics: Tobramycin (TOBI) for Pseudomonas, aztreonam (Cayston).

    • Intravenous antibiotics: Piperacillin/tazobactam, tobramycin, fluoroquinolones.

Cystic Fibrosis Modulators and Genetic Therapies

CFTR Modulators Overview

  • Families of drugs developed to target the dysfunctional CFTR protein which include:

    • Potentiators: Enhance the function of existing CFTR proteins.

    • Correctors: Promote correct processing and trafficking of CFTR to cell membranes.

  • Ivacaftor: First mutation-specific drug for CF that enhances chloride transport. Evidence suggests it improves lung function and reduces exacerbations.

Combination Therapies

  • Ivacaftor + Lumacaftor: Improve outcomes in patients who are homozygous for the F508del mutation.

  • Newer combinations targeting multiple mutations continue to evolve, including triple therapies (e.g., elexacaftor + tezacaftor + ivacaftor) approved for various age groups.

Future of CF Treatment

  • Emerging strategies for a potential cure include:

    • Gene editing technologies (e.g., CRISPR-Cas9).

    • Advances focusing on gene therapies that offer repair or replacement options.

Trends and Predictions in CF Patient Demographics

  • Increasing patient population and survival rates.

  • Reference data from CFF registry shows significant increases in population aged 40+.

  • The trend indicates improved management and therapeutic effectiveness over the years.

Clinical Cases and Discussion Points

  • Clinical evaluation prompts for CF-related questions.

    • For example, the implications of bronchiectasis on treatment protocols in children with CF.

    • Common drugs for mucolytic therapy.

    • Likely pathogens cultured in young CF patients.

Conclusion

  • Emphasis on the ongoing research in CF therapies demonstrates an evolving understanding of the disease mechanisms and management strategies.

Additional Notes on Genetic Modification Techniques

  • Various techniques such as CRISPR, prime editing, and TALEN are mentioned as potentials in future CF therapies.